ArticleScientific reports2026
Physcion-8-O-β-D-monoglucoside protects hepatocytes from TNF-α-mediated apoptosis by suppressing the PI3K/AKT/NF-κB signaling pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Physcion-8-O-β-D-monoglucoside (PMG) is one of the active ingredients of Radix et Rhizoma Rhei, which has been used for treating liver diseases for hundreds of years in China. However, the hepatoprotective effects of PMG remain poorly understood. This study aimed to investigate the mechanism of the protection effects of PMG on tumor necrosis factor-α (TNF-α)-induced hepatotoxicity. We developed both in vitro and in vivo models of liver injury to assess the protective effects of PMG against TNF-α-induced hepatotoxicity. The in vitro model employed TNF-α/actinomycin D in AML-12 cells, while the in vivo model utilized intraperitoneal injection of carbon tetrachloride (CCl4) in mice. Interactions of PMG and TNFR1 (the receptor of TNF-α) were explored by molecular docking. AAV resuspension was administered before PMG treatment via intravenous injection to overexpress TNF-α in the CCl4-induced mice. The effects of PMG on liver injury were assessed using CCK-8 assay, AST/ALT level measurement, and HE staining. Cell apoptosis was detected through Hoechst staining, TUNEL staining, and the levels of cleaved caspase-3. mRNA expression of TNF-α and IL-6 was quantified using real-time PCR, while the related proteins were detected by Western blotting. The protein localization of TNF-α was visualized by immunofluorescence assays. PMG effectively protected against hepatotoxicity in vitro and in vivo by restoring cell survival, decreasing AST, ALT, and reducing apoptosis. TNF-α overexpression counteracted the hepatoprotective effects of PMG, thereby attenuating its regulatory impacts on apoptosis and the dysregulation of the PI3K/AKT/NF-κB signaling pathway. Notably, PMG ameliorated hepatotoxicity by restoring the TNF-α-mediated apoptosis signaling pathway, supporting its potential as a novel therapeutic for acute liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.